52/100Is DOCS-Doximity, a buy?
Friday 7 August 2026
Why now: DOCS is trading at about $35.93 in premarket, up roughly 66% versus the prior close, which signals a major new information event that can reset sentiment. The timing edge is watching whether this gap becomes a durable re-rating after a weak 90-day trend rather than a one-day spike.
Upside: If the market accepts a higher earnings and guidance base, the upside path is a rerating toward prior valuation ranges rather than incremental multiple expansion. Using the Wall Street target of $25.29 as a reference point, the stock is already trading well above that level premarket, so near-term upside is no longer “easy.”
Risks: The biggest risk is that the gap fades because the longer-term trend and industry relative strength were weak before this report, and the stock fails to hold higher prices once the initial excitement passes. A second key risk is that growth stays modest and the valuation case depends on very high margins staying intact.
Sign up or log in for access
Unlock the full scorecard, detailed analysis, and research notes. Free — no credit card needed.
Scorecard
| Scorecard | 52/100 | |
|---|---|---|
| Company Detail | DOCS - Doximity, Inc. | |
| Price as at 6 August 2026 | $20.66 | |
| Market cap | $3.9B | |
| Quality and Fundamental Score (100) | ||
| Breakout / Early-Momentum /20 | 0/20 | |
| Rev/EPS Momentum /20 | 13/20 | |
| Business Quality /15 | 12/15 | |
| Balance Sheet /15 | 13/15 | |
| Valuation /10 | 7/10 | |
| Industry Relative Strength /10 | 2/10 | |
| Macro / Sector Tailwind /10 | 5/10 | |
| Growth | ||
| Cash runway | Cash generative | |
| Revenue YoY | +13.1% | |
| EPS YoY | -11.7% | |
| FCF YoY | +19.0% | |
| Gross margin | 89.1% | |
| Valuation & Trend | ||
| Trailing P/E | 23.2x | |
| Forward P/E | 14.4x | |
| RSI (14d) | 44 | |
| vs 50d SMA | -2.3% | |
| Support cushion | −2.9% | |
| Sentiment | ||
| Wall Street verdict | Mixed | |
| News tone | Quiet | |
| Dividend | — | |
How are these colored?
| Metric | Strong metrics | Solid metrics | Selective | Caution | Unfavourable |
|---|---|---|---|---|---|
| Overall score | ≥ 80 | 70-79 | 60-69 | 50-59 | < 50 |
| Business quality /15 | ≥ 12 | 10-11 | 8-9 | 6-7 | < 6 |
| Balance sheet /15 | ≥ 12 | 10-11 | 8-9 | 6-7 | < 6 |
| Market cap | ≥ $20B | $5B-$20B | $2B-$5B | $1B-$2B | < $1B |
| Cash runway | ≥ 3 yr or cash generative | 1.5-3 yr | 0.75-1.5 yr | 0.25-0.75 yr | < 0.25 yr |
| Revenue YoY | ≥ 15% | 5-15% | 0-5% | -5-0% | < -5% |
| EPS YoY | ≥ 20% | 5-20% | 0-5% | -5-0% | < -5% |
| FCF YoY | ≥ 10% | 1-10% | 0-1% | -5-0% | < -5% |
| Gross margin | ≥ 60% | 40-60% | 25-40% | 10-25% | < 10% |
| Trailing P/E | < 15 | 15-25 | 25-35 | 35-40 | > 40 or neg |
| Forward P/E | < 15 | 15-25 | 25-35 | 35-40 | > 40 or neg |
| RSI (14d) | 50-70 | 45-50 or 70-75 | 40-45 or 75-78 | 30-40 or 78-80 | < 30 or > 80 |
| vs 50d SMA | +2% to +15% | 0-2% or 15-25% | -2-0% or 25-35% | -3--2% or 35-40% | < -3% or > 40% |
| Support cushion | 2-10% above | 0-2% | 10-15% | 15-20% | price below support |
| Wall Street verdict | Aligned | — | Mixed | — | Disagrees |
| News tone | Positive | — | Neutral / Mixed | — | Negative |
| Dividend | Yield ≥ 2% & growing | Growing | Flat payer ≥ 1% | Low / flat | Cutting |
Detailed Analysis — Friday 7 August 2026
Jeffrey A.
Matthew Sonefeldt serves as Chief Financial Officer and Principal Financial Officer.
Receiver of capital expenditure: No — Doximity is usually funded from operating budgets (marketing, recruiting, communications, and clinical workflow software) rather than customers making large, multi-year capital spending commitments.
Main customers
- Pharmaceutical and life sciences companies (They use Doximity to reach clinicians with targeted digital marketing and information, which can be sensitive to marketing budget cycles.)
- Hospitals and health systems (They use recruiting and workflow tools that help connect with clinicians and support day-to-day clinical work.)
- Doximity is a high-margin healthcare platform business with strong cash generation and a balance sheet that does not rely on debt.
- Over a 1+ year horizon, the durable value is tied to clinician engagement and workflow adoption, which can make the platform harder to displace than pure advertising channels.
- The stock, however, is coming off a weak intermediate-term trend, so the opportunity depends on whether the latest results translate into sustained growth confidence rather than a one-quarter reset.
Scores 52 out of 100 — a mixed overall grade. Balance sheet and business quality scored highest. Valuation and earnings trend were fair but not standout drivers. Relative strength versus its industry and chart setup weighed on the total. The score is capped because the last completed daily-bar technical snapshot shows a broken setup (200-day trend not rising, no reclaim, weak industry relative strength) even though the business fundamentals are strong. The current premarket gap is real, but it does not erase the longer window of underperformance and needs time to prove it can hold.
Component scores are on the scorecard above.
- On the last completed daily bar, DOCS showed weak intermediate trend signals (no breakout state, no heartbeat hold above resistance, 200-day moving average not rising, and low industry relative strength versus the healthcare sector).
- Today’s premarket print near $35.93 is a sharp regime change versus that prior close-based snapshot, but the setup still needs confirmation during regular hours and follow-through before it can be treated as a stable trend turn.
- Based on the fact pack, DOCS is profitable with strong cash generation: latest annual revenue was $644.86M, net income was $196.05M, and free cash flow was $317.50M with an 89.1% gross margin.
- The balance sheet is conservatively positioned with $273.60M of cash, a strong current ratio of about 6.08, and net debt to EBITDA negative (more cash than debt on a net basis).
- Red flags to state plainly: share count has risen over time (about 11.69% over 5 years), which means dilution has been a real cost even though the company generates meaningful free cash flow.
- Also, retained earnings are negative in the provided metrics, which is not a liquidity problem here but is a reminder that accounting history and capital return choices matter when valuing a mature, profitable platform.
Cash runway: Cash generative (latest annual free cash flow is positive).
Upcoming (1–6 months)
- Follow the company’s next quarterly reporting cycle for confirmation that the post-earnings gap reflects sustained guidance and not a one-time reset.
Ongoing
- Track whether the stock can hold the post-gap range during regular trading and whether share count growth slows versus prior multi-year dilution.
Risks
- Budget sensitivity: life sciences marketing and recruiting spend can tighten, which would pressure growth even if clinician engagement remains strong.
- Execution and trust risk: pushing monetization too hard can reduce clinician engagement, which would weaken the network effect that supports pricing and margins.
Breaks the thesis
- If the post-earnings gap cannot hold and price decisively falls back below $28.00, it would signal the market rejected the re-rating and the stock is back in a broken trend.